Quantbot Technologies LP Takes $2.23 Million Position in Bio-Rad Laboratories, Inc. $BIO

Quantbot Technologies LP acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 1st quarter, Holdings Channel reports. The firm acquired 9,144 shares of the medical research company’s stock, valued at approximately $2,227,000.

Other large investors have also made changes to their positions in the company. GeoWealth Management LLC lifted its position in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Curat Global LLC purchased a new position in shares of Bio-Rad Laboratories in the first quarter valued at about $34,000. Allworth Financial LP lifted its position in shares of Bio-Rad Laboratories by 260.0% in the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 104 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Bio-Rad Laboratories by 64.1% in the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 139 shares in the last quarter. Finally, Skylands Capital LLC purchased a new position in shares of Bio-Rad Laboratories in the first quarter valued at about $122,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 0.2%

Shares of NYSE:BIO opened at $287.91 on Thursday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99. The company has a 50-day moving average price of $254.72 and a 200 day moving average price of $254.08. The company has a market cap of $7.79 billion, a price-to-earnings ratio of 24.54 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. During the same quarter last year, the firm earned $3.11 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Ratings Changes

BIO has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Royal Bank Of Canada raised their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. UBS Group cut their price objective on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Citigroup cut their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $333.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.